A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes and potentially enhance the effectiveness of existing treatments. Here are some key details about the study:
- The treatment involves a unique combination of therapies that have not been widely tested together before.
- Patients will receive a regimen that includes both established medications and new agents aimed at targeting the cancer more effectively.
- The study is designed to assess how well this combination works in managing the disease and improving patients' quality of life.
- Researchers are particularly interested in understanding the safety and tolerability of this new treatment approach.
- Participants will be closely monitored throughout the study to track their progress and any side effects that may arise.
- This study aims to provide insights into how combining different therapies can lead to better treatment strategies for patients.
Third Opinion AI Generated Synopsis
Trial Summary
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
